Liver Cancer

When it comes to hepatocellular carcinoma (HCC), doctors have a handful of treatment options at their disposal. But how do they decide what’s best?

A caregiver sheds light on the trials and tribulations of his wife's cancer journey and describes his awe in watching his wife's strength.

The Food and Drug Administration approved the combination of Tecentriq and Avastin in patients with unresectable or metastatic hepatocellular carcinoma, making it the first immunotherapy regimen to be approved for this cancer type.

In the spring 2020 issue of CURE®, Editor-in-Chief Dr. Debu Tripathy details how preventing liver cancer starts with understanding the precursors to cancer’s development.

Nonalcoholic fatty liver disease can lead to cancer. Patients can reverse the damage through diet and exercise, but how can they know if they have the common condition?

The Food and Drug Administration’s recent approval of Pemazyre (pemigatinib) is a ‘huge milestone’ for patients with cholangiocarcinoma, according to the advocacy coordinator with the Cholangiocarcinoma Foundation.

Each month, we take a look back at the most popular CURE® stories. Here are the top five stories for April 2020.

A gastrointestinal malignancy expert discusses the role genomics play in cholangiocarcinoma, as well as how genetic profiling may identify which treatment is best for patients.

The Food and Drug Administration approved Pemazyre for the treatment of patients with previously treated, advanced cholangiocarcinoma.

Although the new coronavirus has led to a delay in some cholangiocarcinoma trials, experts don’t expect the trials to come to an end.

The Food and Drug Administration approved the dual immunotherapy of Opdivo and Yervoy for the treatment of patients with advanced hepatocellular carcinoma. Here’s what you need to know.

The Food and Drug Administration granted an accelerated approval to the combination of Opdivo and Yervoy for the treatment of patients with advanced hepatocellular carcinoma who were previously treated with Nexavar.

Researchers hope the new PROOF trial will show that infigratinib, a targeted drug, will expand options in treating advanced cholangiocarcinoma. Patients are enrolling now.

A circulating cell-free DNA test for patients with gastrointestinal cancers has a 90% accuracy rate to detect patients’ cancers and could provide a standard test in the future, according to new study findings.

The combination treatment of Tecentriq (atezolizumab) and Avastain (bevacizumab) improved patient-reported outcomes and quality of life in a recent phase 3 study.

Radiofrequency ablation was statistically on par with surgery when it came to survival after an early recurrence of liver cancer, but surgery provided more benefit if the disease was a bit more advanced.

Patients with hepatocellular carcinoma whose tumors couldn’t be surgically removed lived longer and experienced few side effects after stereotactic body radiotherapy, according to phase 2 study findings.

The FDA has granted a priority review to a new drug application (NDA) for pemigatinib as a treatment for patients with previously treated, locally advanced or metastatic cholangiocarcinoma – a cancer that originates in the bile ducts – with FGFR2 fusions or rearrangements, according to Incyte, the agent’s manufacturer.

While radiation therapy may be a common alternative for inoperable hepatocellular carcinoma, two new studies suggest that proton radiation therapy may offer the same benefits as the more traditionally used photon radiation therapy, with less toxicity.

Nearly one-quarter of inoperable intrahepatic cholangiocarcinomas shrank enough to make surgery possible after selective internal radiation was added to chemotherapy, a study shows.

Both men and women have seen an increase in liver cancer diagnoses and death over the past nearly 20 years, according to new study findings.

For Liver Cancer Awareness Month, here’s a round-up of the latest news and updates in this disease space.

Frontline treatment with Opdivo improved overall survival and response rates among patients with advanced hepatocellular carcinoma, however, the trial missed its primary endpoint.

As immunotherapies emerge in the treatment of liver cancer, experts examine whether two or more is better than one.